Results 191 to 200 of about 57,191 (243)
Some of the next articles are maybe not open access.

ABP 980: A Trastuzumab Biosimilar

BioDrugs, 2018
ABP 980 (KANJINTI™) is a biosimilar of the reference anti-HER2 antibody trastuzumab. In the EU, ABP 980 is approved for use in all indications for which reference trastuzumab is approved, including HER2-positive early breast cancer, metastatic breast cancer and metastatic gastric cancer.
openaire   +2 more sources

ABP en Nederzettingen

2014
Financieele ...
Handmaker, Jeff   +2 more
openaire   +1 more source

Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients With Inflammatory Arthritis: A Real Life Retrospective Analysis

Journal of Personalized Medicine, 2022
Maria Chiara Ditto   +2 more
exaly  

Home - About - Disclaimer - Privacy